Bone marrow transplant rejection is a complication that occurs after a stem cell or bone marrow transplant has been done, as the newly transplanted donor cells attack the transplant recipient's body. The symptoms of the bone marrow transplant rejection include chest pain, chills, drop in blood pressure, fever, flushing, headache, hives, nausea, pain and shortness of breath. The disease is mainly treated through immunosuppressive drugs.
A bone marrow transplant involves taking cells that are normally found in the bone marrow (stem cells), filtering those cells, and giving them back either to the donor (patient) or to another person. Bone marrow transplant has been used successfully to treat diseases such as leukemias, lymphomas, aplastic anemia, immune deficiency disorders, and some solid tumor cancers since many years. The drug candidates in the pipeline for bone marrow transplant rejection include, T cell replacement therapy, Leukocyte stem cell therapy and Lisofylline.
Some of the companies having drugs in the bone marrow transplant rejection pipeline include AbbVie Inc., AbGenomics International, Inc. Bellicum Pharmaceuticals, Inc. and Bristol-Myers Squibb Company.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.